The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD
Abstract
OBJECTIVE: Bile acids are regulators of lipid and glucose metabolism, and modulate inflammation in the liver and other tissues. Primary bile acids such as cholic acid and chenodeoxycholic acid (CDCA) are produced in the liver, and converted into secondary bile acids such as deoxycholic acid (DCA) and lithocholic acid by gut microbiota. Here we investigated the possible roles of bile acids in non-alcoholic fatty liver disease (NAFLD) pathogenesis and the impact of the gut microbiome on bile acid signalling in NAFLD. DESIGN: Serum bile acid levels and fibroblast growth factor 19 (FGF19), liver gene expression profiles and gut microbiome compositions were determined in patients with NAFLD, high-fat diet-fed rats and their controls. RESULTS: -taurocholate cotransporting polypeptide and paraoxonase 1, no change in mRNA expression for small heterodimer partner and bile salt export pump, and reduced serum FGF19 were evidence of impaired FXR and fibroblast growth factor receptor 4 (FGFR4)-mediated signalling in NAFLD. Taurine and glycine metabolising bacteria were increased in the gut of patients with NAFLD, reflecting increased secondary bile acid production. Similar changes in liver gene expression and the gut microbiome were observed in high-fat diet-fed rats. CONCLUSIONS: The serum bile acid profile, the hepatic gene expression pattern and the gut microbiome composition consistently support an elevated bile acid production in NAFLD. The increased proportion of FXR antagonistic bile acid explains, at least in part, the suppression of hepatic FXR-mediated and FGFR4-mediated signalling. Our study suggests that future NAFLD intervention may target the components of FXR signalling, including the bile acid converting gut microbiome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Jiao et al. (2018) found that MAFLD patients present elevated primary and secondary bile acids, among which the proportion of DCA is increased and CDCA is decreased.”
From Akkermansia muciniphila alleviates high‐fat‐diet ‐related metabolic‐associated fatty liver disease by modulating gut microbiota and bile acids (2023) · cites this paper as Jiao et al. (2018)
In the citing paper
“Additionally, hepatic CYP7A1 expression is enhanced.”
From Akkermansia muciniphila alleviates high‐fat‐diet ‐related metabolic‐associated fatty liver disease by modulating gut microbiota and bile acids (2023) · cites this paper as Jiao et al. (2018)
In the citing paper
“With increasing severity of NASH and fibrosis, BA levels tend to increase and the composition of BAs changes”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [91]
In the citing paper
“First, the gut microbiota may affect gastrointestinal transit through its regulation of BA synthesis. The gut microbiota is equipped with enzymes for the production of secondary BAs, which may suppress the FGF19- and FXR-mediated signaling, leading to the induction of CYP7A1 [ 49 , 50 ], and consequently elevated de novo BA synthesis and improved colonic transit.”
From Role of gut microbiota in functional constipation (2021) · cites this paper as [49]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences
Langille, M. G. I., Zaneveld, J., Caporaso, J. G., McDonald, D., Knights, D., Reyes, J. A., Clemente, J. C., Burkepile, D. E., Vega Thurber, R. L., Knight, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2676 · Cited by 9,116
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Vernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Research works printed but not linked: 1
- 10.1172/JCI200421025 · DOI
Cited by
Sorted by citations
Items 601–700 of 736
Chen, Y.-J., Yang, B.-W., Gu, Z.-C., & Han, J. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1767462 · Cited by 2
“…excessive formation of hydrophobic secondary bile acids (for example deoxycholic acid), FXR–FGF19 feedback can be impaired and pro-lipogenic and pro-inflammatory hepatic programs are unmasked—an outcome documented in both mechanistic micro-biome–bile-acid studies and models of NAFLD (107, 108).”
Gajendiran, T. Y., Ganamurali, N., & Sabarathinam, S. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104683 · Cited by 2
Multiple roles of bile acids in ferroptosis regulation: Opportunities for disease therapy
Wu, N., Yu, S., Wei, X., Yang, L., & Zhang, X. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108224 · Cited by 2
Bile acid signaling: from dynamic pool composition to inter-organ communication
Yang, F., Wei, T., Liu, K. L., Chu, H., & Yang, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1890710 · Cited by 2
“For example, patients with metabolic dysfunction-associated steatotic liver disease (MASLD) often show abnormal BA metabolism, including elevated total BA levels and altered secondary BA composition (11).”
Molecular mechanisms and pathogenesis of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10529-0 · Cited by 3
“In addition to endotoxins, intestinal microbial metabolites, including secondary bile acids, have an instrumental role in modulating MASH and liver cancer, and multiple studies have shown an increase in total serum and faecal bile acids in patients with MASH 260,261 .”
Schneider, K. M., & Trautwein, C. (2020) · Wiener klinisches Magazin · doi:10.1007/s00740-020-00353-1 · Cited by 2
The Microbiome, Metabolism, and Networks in Precision Nutrition
Mensah, G. E., Maseng, M. G., Allard, S., & Gilbert, J. A. (2024) · Precision Nutrition · doi:10.1016/b978-0-443-15315-0.00011-0 · Cited by 2
Sheng-Jiang powder ameliorates NAFLD via regulating intestinal microbiota in mice
Zhang, P., Li, J., Miao, Y., Zhao, X., Zhu, L., Yao, J., Wan, M., & Tang, W. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1387401 · Cited by 3
Self-citationMahdizadeh, F., Sobhi, P., & Banaei, S. (2025) · Clinics And Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102547 · Cited by 3
Serum Metabolomic Analysis of Healthy and Central Precocious Puberty Girls
Xia, Y., Li, L., Li, D., Liu, Y., & Hao, L. (2025) · Clinical Endocrinology · doi:10.1111/cen.15226 · Cited by 2
“Bile acid signalling is associated with fatty liver disease, NAFLD, Alz-heimer's disease, and inflammatory bowel disease [34, 35].”
Xu, Y., Zhang, F., Ke, Z., Lin, Y., Zhang, Y., Liu, Y., Zhang, Y. Y., Xu, J., & Liu, Y. (2025) · Liver International · doi:10.1111/liv.70130 · Cited by 2
“Similar to previous investigations [35], this study also observed significant differences in the concentration and compositions of bile acid pools between individuals with MAFLD and healthy individuals.”
The Roles and Clinical Significance of Major Hepatic‐Derived Metabolites in Hepatocellular Carcinoma
Sun, R., Wang, X., Ma, J., Cai, Y., Li, L., & Wang, S. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70008 · Cited by 2
“BAs, the principal constituents of bile, are broadly categorized into primary and secondary types according to their origin [17].”
Evaluation and impact of different biomarkers for early detection of hepatocellular carcinoma
Best, J., Sydor, S., Bechmann, L. P., & Canbay, A. E. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2020.56 · Cited by 2
“In NASH patients, the abundance of bile salt hydrolase (an enzyme involved in deconjugation of bile acids) expressing bacteria is shifted, which leads to increased bile acid levels as well as an altered composition of the bile acid pool tending to an increased amount of secondary conjugated bile acids([92]).”
BackgroundAdvances in metformin for the treatment of non-alcoholic fatty liver disease in children
Wu, Q., Zeng, S., Peng, J., Yuan, Y., Zhu, Z., Xie, Z., Huang, Z., Huang, J.-S., Lai, J., Chen, J.-A., et al. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2118112 · Cited by 2
“higher than in normal children, indicating that excessive bile acids can contribute to NAFLD development [25].”
BackgroundLi, H., Ma, J., Gu, L., Jin, L., Chen, P., Zhang, X., & Chen, L. (2020) · doi:10.21203/rs.3.rs-27123/v1 · Cited by 2
“Another study observed the increased FXR antagonistic deoxycholic acid and decreased FXR agonistic chenodeoxycholate in percentage, by which inhibited the FXR signalling in the liver of NASH patients[21].”
BackgroundThe importance of bile Acids in NAFLD: current evidence and future directions
Rivera‐Andrade, A., & Álvarez, C. S. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100773 · Cited by 2
Huang, C., Luo, Z.-Z., Huang, W., Lin, L.-P., Yao, Y.-T., Zhuang, H.-X., Xu, Q., & Lai, Y. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i1.102034 · Cited by 1
Metabolische Dysfunktion-assoziierte steatotische Lebererkrankung und hepatozelluläres Karzinom
Best, J., Kälsch, J., Krawczyk, M. J., Manka, P. P., Canbay, A. E., Schmidt, H., & Jochheim, L. S. (2025) · Die Gastroenterologie · doi:10.1007/s11377-025-00878-z · Cited by 1
“DadurchnimmtdieMengeansekun-dären konjugierten Gallensäuren tenden-ziell zu [34].”
Luo, X., Yang, W. P., Kang, Y., Ma, S., Fan, Y., Du, J., Luo, H., Wang, X., & Deng, F. (2025) · The Journal of Vascular Access · doi:10.1177/11297298251332047 · Cited by 1
“33 In patients with AVF stenosis, the physical barrier of the intestine is impaired, the intestinal permeability is enhanced, and the proportion of bacteria producing secondary bile acids in the intestinal microbiota in the body is significantly increased, and deoxycholic acid, as one of the types of bile acids, can a…”
Sun, Y.-M., Kuang, J., Zhang, H.-H., Xia, X.-X., Wang, J.-Y., Zheng, D., Zhou, K., Tang, Y., Zhao, A., Jia, W., et al. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i6.103616 · Cited by 1
Li, N., Zhu, T., Dong, Y., Zhao, C., Chen, J., Tian, Y., Liu, Y., Hong, X., & Xiong, H. (2025) · Biomedical Chromatography · doi:10.1002/bmc.70143 · Cited by 1
Yu, X., Shupei, M. A., Zhang, D., Chen, X., OUYANG, J., Xi, B., Xie, D., & Shi, Y. (2025) · Chinese Journal of Analytical Chemistry · doi:10.1016/j.cjac.2025.100579 · Cited by 1
Zhang, J., Tong, X., Lin, W., Issa, R., Wang, L., Zhang, B., Zhu, G., Ran, J., Zhao, Q., Yin, S., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003691 · Cited by 1
“[10] Given FXR’s central role in regulating BAs and related metabolic pathways, FXR-targeting agonists have become a promising therapeutic strategy for NAFLD.”
Microbiota and fatty liver disease: Potential candidate for therapeutic intervention
Eslami, M., Naderian, R., Tarahomi, M., Babaeizad, A., Amini, P., & Pouya, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00026-3 · Cited by 1
Lee, S. H., Kim, J. H., Lee, S. R., Lee, B. S., Kim, K. H., Jun, D. W., Kim, C. S., & Kang, K. A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1707492 · Cited by 1
Li, M., Li, H., Zou, J., Li, R., Zhang, H., Yang, W., Wu, X., & Sun, C. (2025) · Food & Function · doi:10.1039/d5fo04199f · Cited by 1
Sevelamer inhibits the formation of cholesterol gallstones by modulating bile acid metabolism
Shen, S., Ning, M., Li, M., Qian, S., Ye, X., Zhuang, Q., Wu, S., Wan, X., & Dong, Z. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1737631 · Cited by 1
Metabolomics identifies chenodeoxycholic acid as a protective factor in diabetic foot ulcers
Li, Y., Guo, R., Lv, L., Jiang, T., Zhang, C., Chang, J., Hu, K., Peng, H., Chen, L., Chen, R., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1754743 · Cited by 1
Lactobacillus murinus Alleviates High Fructose‐Induced MASLD by Boosting Arginine Production
Mo, X., Zhao, G., Liu, L., Zhen, L., Huang, Q. Y., Wang, Y., Yang, X., Huang, L., Wan, L., Wei, C., et al. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.71502 · Cited by 1
Xu, F.-P., Yang, C., Yu, S., Cai, H., Hui, M.-Y., Fang, L., Chen, G., Jiang, S., Qi, S.-L., Wu, S.-J., et al. (2026) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2026.03.003 · Cited by 2
Self-citationGut Microbiota Mediates HFPO–DA-Induced Hepatotoxicity via Arginine Reprogramming in Lean NAFLD Mice
Ding, R., He, L., Guo, R., Tian, X., Chen, L., Zhan, N., Chen, L., Wu, Y., ZHANG, J., & Zhao, F. (2026) · Environmental Science & Technology · doi:10.1021/acs.est.6c02839 · Cited by 1
Bile acid-mediated regulation of pyroptosis in PCOS: a hypothesis for hepato-ovarian axis
Avcioglu, S. Y., & Berkel, Ç. (2026) · Comparative Clinical Pathology · doi:10.1007/s00580-026-03789-9 · Cited by 1
Song, S., Wang, L., Li, L., Bai, S.-H., Zhu, X., Zhang, X.-L., Deng, C.-H., & Han, Z. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218567 · Cited by 1
Wu, L., Li, S., Han, F., Guo, J., Zhang, X., & Xu, L. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1801367 · Cited by 2
“The future lies in longitudinal “time-series” studies that track the same individuals over time, under different conditions (e.g., during shift work schedules, before and after TRE or phytochemical interventions) (Jiao et al., 2018).”
Liu, A., Yang, T., Li, Z., Luo, R., Zhu, C., Du, S., Chen, W., & Duan, J. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104253 · Cited by 1
The gut microbiota-bile acid-FXR axis in NAFLD: from progression to therapeutic applications
Zheng, W., Feng, Q., Wang, J., Li, X. X., & Yin, S. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1811118 · Cited by 1
“Notably, patients with NASH exhibit 9.3-fold increased expression of CYP7A1 in the liver, along with 2.83-fold increased expression of CYP27A1 and 2.18-fold increased expression of CYP8B1, which leads to increased levels of DCA and decreased levels of CDCA in serum (Jiao et al., 2018).”
InfluentialYoon, S. J., Eom, J. A., & Suk, K. T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1864805 · Cited by 1
Peloso, A., Lacotte, S., Gex, Q., Slits, F., Moeckli, B., Oldani, G., Tihy, M., Hautefort, A., Kwak, B. R., Rubbia‐Brandt, L., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0296265 · Cited by 1
Impact of Novel Functional Ingredients on Lactobacillus casei Viability
Alemán, R. S., Ruiz, F. D., Sarmientos, M., Marcía-Fuentes, J. A., Yaday, A., & Aryana, K. J. (2024) · Bacteria · doi:10.3390/bacteria3010003 · Cited by 3
“The liver eliminates toxins, excess cholesterol, and impurities of one kind [22].”
BackgroundLu, W., Chen, J., Guo, Y., Wang, Z., Gao, W., & Liu, M. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120572 · Cited by 1
Lewkowicz, M., Jones, M., Kovačević, B., Ionescu, C. M., Wagle, S. R., Foster, T., Mikov, M., Mooranian, A., & Al‐Salami, H. (2022) · Therapeutic Delivery · doi:10.4155/tde-2022-0033 · Cited by 1
Gridnyev, O., Fadieienko, G. D., Kushnir, I. Е., & Gridnieva, S. V. (2023) · Modern Gastroenterology · doi:10.30978/mg-2023-1-55
“Дослідження також показали збільшення експресії оклюдину, ZO-1 і клаудину-2 під впливом бутирату [187].”
InfluentialSkinner, R. C. (2019) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.3916 · Cited by 1
“Reference Dietary study characteristics Results Apple Pomace Constituents Chen, et al. (2017) [23] Male Kunming mice age 45d n=18 animals/group 45% HFD with 200, 400, or 800 mg/kg bwt/d apple pomace polysaccharide extract for 30 days 200 mg/kg bwt/d ↓ serum cholesterol ↓ serum insulin ↓ serum adiponectin ↓ serum lepti…”
BackgroundMethodInfluentialThe gut microbiome and gut-liver axis in NAFLDPreprint
Guo, C., Ji, J., Wu, J., Wu, L., Feng, J., Li, J., Yu, Q., Dai, W., Li, Y., & Zheng, Y. (2024) · doi:10.22541/au.170666810.08665505/v1
Schneider, K. M., & Trautwein, C. (2020) · Die Gastroenterologie · doi:10.1007/s11377-019-00402-0
Intestinal-derived FGF15 preserves muscle and bone mass following sleeve gastrectomyPreprint
Bozadjieva-Kramer, N., Shin, J. H., Shao, Y., Gutiérrez‐Aguilar, R., Li, Z., Heppner, K. M., Chiang, S., Vargo, S. G., Granger, K., Sandoval, D. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.02.130278
“Other studies report that basal FGF19 levels are inversely correlated to glucose metabolism or insulin sensitivity (Barutcuoglu et al., 2011; Sonne et al., 2016) and nonalcoholic fatty liver disease (NAFLD) (Eren et al., 2012; Jiao et al., 2018).”
BackgroundInfluentialCommon transcriptional programme of liver fibrosis in mouse genetic models and humansPreprint
Cokan, K. B., Urlep, Ž., Moškon, M., Mraz, M., Kong, X. Y., Eskild, W., Rozman, D., Juvan, P., & Režen, T. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.02.364901
Environment-host-microbe interactions shape human metabolism
Chen, L., & Fu, J. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.171839167
Lim, Y. S. (2019) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/139651
Tian, M., Yan, J., Zhang, H., Wei, Y., Zhang, M., Rao, Z., Zhang, M., Wang, H., Wang, Y., & Li, X. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3944517
Song Lyrics--Gateway to the Interpretation of Poetry.
Saunders, J. (1994) · English in Texas
The Relationship between Intestinal Dysbacteriosis and Liver Cirrhosis
雷, 丹. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.124362
Porras, D. (2021) · Buleria (Universidad de León) · doi:10.18002/10612/13641
Gao, W., Gao, X., Zhu, L., Gao, S., Sun, R., Feng, Z., Wu, D., Liu, Z., Zhu, R., & Jiao, N. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.04.527090
Self-citationPathophysiology of Bile Acid Regulation
Sujka, J. A., & DuCoin, C. G. (2023) · Springer eBooks · doi:10.1007/978-3-031-25828-2_7
Endogenous bile acids are associated with body lipid accumulation in non-diet induced obese pigsPreprint
Hu, Y., Wu, A., Yan, H., Pu, J., Luo, J., Zheng, P., Luo, Y., Yu, J., He, J., Yu, B., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2935539/v1
Yehya, Y. M., El-Said, Z. H., Adel, M., Othman, B., Mansour, A. A., & Gad, S. (2023) · Egyptian Journal of Basic and Applied Sciences · doi:10.1080/2314808x.2023.2229107
“FGF-19 deficiency in NASH may be due to an unfavorable bile acid composition [42].”
BackgroundProgress on the Role of “Gutbacteria-Gut-Liver Axis” in Non-Alcoholic Fatty Liver Disease
陈, 孟. (2023) · Medical Diagnosis · doi:10.12677/md.2023.132038
Liang, Y., Fu, J., Shi, Y., Jiang, X. P., Lü, F., & Liu, S. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4513573
Association of Bile Acid with White Matter Hyperintensity in Cognitively Normal Older Adults
Xu, X. K., Zhang, Y., Lu, X. J., & Shi, B. (2023) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.spl.698
“LASSO is an improved form of least square regression that uses a regularization parameter lambda (λ) to penalize a complex model.”
BackgroundMethodInfluentialMechanism for FXR to regulate bile acid and glycolipid metabolism to improve NAFLD
Huang, Z. G., & Zhou, R. (2023) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v31.i19.797
Primary Bile Acid Disorders: A Largely Unknown Group of Rare Genetic Diseases in Newborns
Bittmann, S. (2024) · Asian Journal of Pediatric Research · doi:10.9734/ajpr/2024/v14i5340
Gut Microbiota and Metabolomics Correlation in a Mouse Model of Acute-on-Chronic Liver FailurePreprint
Teng, X., Yang, L., Tang, H., & Bai, L. (2024) · Research Square · doi:10.21203/rs.3.rs-4346607/v1
Bile Acids and Gestational Diabetes Mellitus: Exploring the Link and ImplicationsPreprint
Lu, C., Gao, Z., & Lei, X. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4869474
Advances in the Study of the Relationship between Post-Cholecystectomy and NAFLD
杨, 艳. (2024) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2024.32083
Bacteroides thetaiotaomicron enhances H 2 S production in Bilophila wadsworthiaPreprint
Davies, J., Mayer, M. J., Juge, N., Narbad, A., & Sayavedra, L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.14.618174
The Role of the Intestinal Microbiota in NAFLD Onset and Progression
Pinheiro, I. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1007741
Joseph, S., de Buyl, S., Leclercq, I. A., & Clerbaux, L. (2025) · medRxiv · doi:10.1101/2025.01.12.25320430
Dietary fiber-based products: Microbiota-oriented intervention
Tan, H., Yang, C., & Nie, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21630-5.00016-2
Tian, Y., Yang, L., Liao, W., Xia, J., Wang, Y., Shi, Y., Xia, H., Pan, D., Wang, S., Yang, C., et al. (2025) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250459
Goonetilleke, M., Correia, J., Chen, Y., McDonald, H., Chan, S. T., Inocencio, I. M., Cross, J., Greening, D. W., Simpson, I. A., Sievert, W., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-5679779/v1
Research Progress on the Influence and Mechanism of Bile Acid Metabolism in Digestive System Tumors
云, 洁. (2025) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2025.42150
Sirchak, Y. S. (2025) · ScienceRise Medical Science · doi:10.15587/2519-4798.2025.329828
Li, S., Jin, C., & Duan, Z. (2025) · Research Square · doi:10.21203/rs.3.rs-6871240/v1
Hmar, E. B. L., Perera, V., Sarma, H., Chandrasiri, S., Kumarasinghe, P., Wikramaratne, N., & Sharma, H. K. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10901-9 · Cited by 1
“Conversely, in the context of BAs dysregulation among individuals with NAFLD, there is a notable increase in both total serum and faecal BA levels [100], attributed to heightened BAs synthesis, upregulation of bile acid transporters, and elevated hepatic BAs concentrations.”
Effects of swimming training on cecum microorganisms and metabolites in rats with high fat diet
Dong, C., Chen, L., Li, D., Zhang, X., & Chen, Y. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1569239
Pinheiro, M. M., Afonso, M. B., & Rodrigues, C. M. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-823524-9.00003-4
Bacil, G. P., Romualdo, G. R., & Barbisan, L. F. (2025) · Springer eBooks · doi:10.1007/978-3-031-93459-9_21
Ng, D. Z. W., Low, A., Sani, K. R. B. K., Liu, L., Zhang, Z., Koh, X. Q., Zhu, M., Mitra, K., Muthiah, M. D., Dan, Y. Y., et al. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00497
Chien, S.-C., Chen, C., Tsai, H., Lin, Y., Shiesh, S., Cheng, P., Chiu, H., Chiu, Y., Lin, Y.-H., Wu, M.-S., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101616
“13 In our study, the substantial upregulation of CYP7A1 and other BA-related genes, accompanied by a modest increase in BA exporter genes, suggests a relatively cholestatic profile in MASH, which may partially explain the elevated serum BA levels and dysregulation of BA homeostasis in these…”
Qadri, S. U., Haas, J. T., Jäntti, S. E., Porthan, K., Juuti, A., Penttilä, A. K., Arola, J., Vartiainen, E., Dirinck, E. L., Vonghia, L., et al. (2025) · medRxiv · doi:10.1101/2025.11.18.25340381
Miao, X., Luo, P., Liu, J., Wang, J., & Chen, Y. (2023) · Figshare · doi:10.6084/m9.figshare.23826910
Zeng, F., Su, X., Liang, X., Liao, M., Zhong, H., Xu, J., Gou, W., Zhang, X., Shen, L., Zheng, J.-S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26690359
Li, M., Cheng, D., Peng, C., Huang, Y., Geng, J., Huang, G., Wang, T., & Xu, A. (2023) · Figshare · doi:10.6084/m9.figshare.22949421
Zeng, F., Su, X., Liang, X., Liao, M., Zhong, H., Xu, J., Gou, W., Zhang, X., Shen, L., Zheng, J.-S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25367488
Zeng, F., Su, X., Liang, X., Liao, M., Zhong, H., Xu, J., Gou, W., Zhang, X., Shen, L., Zheng, J.-S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26690362
Zeng, F., Su, X., Liang, X., Liao, M., Zhong, H., Xu, J., Gou, W., Zhang, X., Shen, L., Zheng, J.-S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25367299
Zeng, F., Su, X., Liang, X., Liao, M., Zhong, H., Xu, J., Gou, W., Zhang, X., Shen, L., Zheng, J.-S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26690356
Wang, Z., He, H., Xie, Y., Li, J., Luo, F., Sun, Z., Zheng, S., Yang, F., Li, X., Chen, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25310083
Zhang, Y., Wang, L., Qi, J., Yu, B., Zhao, J., Pang, L., Zhang, W., & Bin, L. (2024) · Figshare · doi:10.6084/m9.figshare.26588019
Iguchi, K., Seki, N., Sugiura, Y., Maeda, R., Nakano, K., Kawai, T., Okuda, Y., Kamimura, R., Uchida, Y., Hamasaki, A., et al. (2025) · Gut Microbes Reports · doi:10.1080/29933935.2025.2607927
“9,10 In our patients with PPSLD, CA levels increased significantly (12-fold), overshadowing the fivefold increases in DCA and CDCA, suggesting a pronounced shift toward FXR-antagonistic or FXR-neutral bile acids.”
Wang, Z., Wang, D., Liu, Y., Jian, Z., Wang, M., & Lin, H. (2026) · Poultry Science · doi:10.1016/j.psj.2026.106376
Zhu, L., Yang, S., He, C., Pan, H., Fang, C., & Shi, F. (2026) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-025-06305-0
“As pivotal signaling molecules and metabolic regulators, BAs regulate essential physiological and pathological processes, such as glucose metabolism [5], immune regulation [6], and the pathogenesis of liver diseases [7].”
Self-citationProbiotics for managing non-alcoholic fatty liver disease: efficacy and mechanistic insights
Ghosh, S., Ghosh, A. J., Adhikari, M. D., Tiwary, B. K., & Saha, T. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01861-3
“…probiotics from Lactobacillus group have shown the restoration of bile acid composition and suppression of inflammation, while FXR agonists, like obeticholic acid, demonstrated improved Generally, BAs act through Takeda G protein-coupled receptor 5 (TGR5), and farnesoid X receptor (FXR) [ 120].”
Yu, S.-R., Sun, R., Shi, M.-Y., Yang, M., Chen, K., Pan, Q., Zhao, L., Wu, M.-Y., & Chai, J. (2026) · Liver Research · doi:10.1016/j.livres.2026.02.001
“10 These findings indicate distinct BA signatures in IBD and MASLD; however, critical questions remain regarding their shared and disease-specific characteristics.”
刘, 漪. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.162731
Ding, L., Ren, S., Zang, C., Zheng, L., Jiang, L., Guo, H., Yang, W., Guan, H., & Liu, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-42966-2
“…lipid and glucose homeostasis by activating the FXR. CSE-induced enrichment of taurine—a key conjugate for bile acid synthesis—likely facilitates the activation of the intestinal FXR-FGF15 signaling axis, thereby suppressing hepatic lipogenesis and enhancing fatty acid β - oxidation 40,41 .”
Wang, W. J., Ma, L., Chen, Y., Kuang, R., Wang, F., & Wang, L. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004003
Metadata
- Authors
- Jiao, N., Baker, S. S., Chapa-Rodriguez, A., Liu, W., Nugent, C. A., Tsompana, M., Mastrandrea, L., Buck, M. J., Baker, R. D., Genco, R. J., Zhu, R., & Zhu, L.
- Affiliations
- Tongji University (CN)
- University at Buffalo, State University of New York (US)
- Department of Pediatrics, Digestive Diseases and Nutrition Center, The State University of New York at Buffalo, Buffalo, New York, USA
- Corresponding author
- Baker, Susan S
- Zhu, Lixin
- ORCID
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2017-08-03
- Volume
- 67
- Issue
- 10
- Pages
- 1881-1891
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2605955022
- Cited by
- 737
- References
- 50
- Citations by year
- 2026: 81 · 2025: 112 · 2024: 128 · 2023: 105 · 2022: 93 · 2021: 83 · 2020: 68 · 2019: 44 · 2018: 17 · 2017: 4
- FWCI
- 15.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Gut (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- GEM Community of Excellence, the University at Buffalo
- the University at Buffalo Departmental Start-Up Fund
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
- the Peter and Tommy Fund, Inc., Buffalo, NY
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- non-alcoholic fatty liver disease, bile acids, bile acid signaling, farnesoid X receptor, FGFR4, FGF19, gut microbiota, secondary bile acids, deoxycholic acid, lithocholic acid, taurine metabolism, hepatic gene expression, high-fat diet
- MeSH terms
- Gastrointestinal Microbiome, Receptor, Farnesoid X-Activated, Animals, Bile Acids and Salts, Cholesterol 7-alpha-Hydroxylase, Female, Fibroblast Growth Factors, Humans, Male, Middle Aged, Signal Transduction, Receptors, Cytoplasmic and Nuclear, Gene Expression Profiling, Rats, Diet, High-Fat, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
